MetaCap

Metagenomi Therapeutics (MGX) vs Pelthos Therapeutics (PTHS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Metagenomi Therapeutics (MGX) has outperformed Pelthos Therapeutics (PTHS) over the past year, losing 62.6% versus a loss of 74.9%. Pelthos Therapeutics is the larger company by market cap ($25.1 million vs $21.4 million), about 1.2 times the size. Pelthos Therapeutics converts more of its revenue into profit, with a net margin of -257.9% versus -348.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MGX-62.58%PTHS-74.88%
+27%-26%-80%
Nov 21, 20251 yearNov 20, 2026
MGX-95.37%PTHS-86.71%
+5%-48%-100%
Feb 12, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MGX versus PTHS key metrics
MetricMGXPTHS
Share price$0.565$6.38
Market cap$21.36M$25.08M
1-day change-7.95%-8.73%
YTD return-65.12%-79.42%
1-year return-62.58%-74.88%
EPS (TTM)$-2.50$-23.86
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$25.21M$16.80M
Revenue growth (YoY)-51.79%—
Net income (latest FY)$-87.87M$-43.32M
Gross margin—76.25%
Operating margin-380.85%-193.09%
Net margin-348.54%-257.93%
52-week high$1.87$31.62
52-week low$0.562$6.02
Distance from 52-week high-69.79%-79.82%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1138.94%+732.92%
Average volume163.21K54.38K
Shares outstanding37.81M3.93M
Employees11392
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MGX has outperformed PTHS by 12.3 percentage points over the past year.
  • Pelthos Therapeutics is more profitable, keeping -257.9 cents of every revenue dollar as net income versus -348.5 cents for Metagenomi Therapeutics.

About Metagenomi Therapeutics

MGX stock →

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees

About Pelthos Therapeutics

PTHS stock →

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees

MGX vs PTHS FAQ

Which is bigger, Metagenomi Therapeutics or Pelthos Therapeutics?

Pelthos Therapeutics (PTHS) is larger, with a market capitalization of $25.08M compared with $21.36M for Metagenomi Therapeutics (MGX).

Which stock has performed better over the past year, MGX or PTHS?

MGX returned -62.58% over the past 12 months, compared with -74.88% for PTHS (price return, excluding dividends). Past performance does not predict future results.

Are Metagenomi Therapeutics and Pelthos Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons